Natco Pharma concludes US FDA inspection with observations

Natco Pharma Limited (BSE: 524816, NSE: NATCOPHARM) announced the conclusion of the U.S. Food and Drug Administration (FDA) inspection at its Pharma Division located in Kothur, Hyderabad. The inspection, which took place from June 9th to June 19th, 2025, resulted in the company receiving seven observations on Form-483. Natco Pharma stated it is confident in its ability to address these observations within the stipulated timeline and remains committed to adhering to current Good Manufacturing Practice (cGMP) standards and supplying high-quality products. The company's manufacturing facilities are approved by several leading regulatory authorities and cater to over 50 global markets.